Jane Street Group LLC Buys 138,400 Shares of CG Oncology, Inc. (NASDAQ:CGON)

Jane Street Group LLC grew its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 240.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 195,951 shares of the company's stock after purchasing an additional 138,400 shares during the period. Jane Street Group LLC owned about 0.29% of CG Oncology worth $7,393,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Ally Bridge Group NY LLC lifted its stake in CG Oncology by 50.5% in the 3rd quarter. Ally Bridge Group NY LLC now owns 263,266 shares of the company's stock valued at $9,933,000 after purchasing an additional 88,390 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in CG Oncology by 114.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company's stock worth $14,325,000 after purchasing an additional 202,262 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in CG Oncology by 876.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 26,660 shares of the company's stock worth $1,006,000 after purchasing an additional 23,931 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its stake in shares of CG Oncology by 811.9% during the second quarter. Deerfield Management Company L.P. Series C now owns 433,540 shares of the company's stock valued at $13,687,000 after purchasing an additional 386,000 shares in the last quarter. Finally, Ensign Peak Advisors Inc bought a new stake in shares of CG Oncology during the second quarter worth about $1,912,000. 26.56% of the stock is owned by institutional investors.

CG Oncology Stock Down 0.4 %

Shares of NASDAQ CGON traded down $0.11 during mid-day trading on Friday, reaching $28.76. 3,368,234 shares of the company's stock traded hands, compared to its average volume of 655,702. CG Oncology, Inc. has a 1-year low of $25.77 and a 1-year high of $50.23. The business has a 50-day simple moving average of $35.23 and a 200 day simple moving average of $34.92.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.30 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. On average, equities research analysts forecast that CG Oncology, Inc. will post -1.32 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $34.54, for a total value of $34,540.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on CGON shares. HC Wainwright restated a "buy" rating and issued a $75.00 price objective on shares of CG Oncology in a report on Friday, December 6th. Roth Capital raised CG Oncology to a "strong-buy" rating in a research note on Tuesday, August 27th. UBS Group began coverage on CG Oncology in a research note on Thursday, October 24th. They set a "buy" rating and a $60.00 target price for the company. Bank of America reiterated a "buy" rating and issued a $65.00 target price on shares of CG Oncology in a report on Tuesday, October 8th. Finally, Roth Mkm assumed coverage on CG Oncology in a report on Tuesday, August 27th. They set a "buy" rating and a $65.00 price target on the stock. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $63.88.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.